Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
First-Ever Trial to Evaluate Whether Olmesartan Medoxomil Prevents Onset of Early Kidney Disease in Type 2 Diabetes Patients
SAN FRANCISCO, May 8 /PRNewswire/ -- Blinded one-year blood pressure (BP) reduction data from the ongoing landmark
study ROADMAP ( R andomized O lmesartan A nd D ...
New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX(TM) Trial
Data show comparable safety for complex patients treated with TAXUS(R) Express2(TM) Stents and bypass surgery
NATICK, Mass., Feb. 18 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the publication of results from its landmark
SYNTAX(TM) trial in this week...
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
- Multaq(R) (dronedarone) significantly reduced the risk of cardiovascular hospitalization or death by 24 percent in patients with atrial fibrillation -
PARIS, Feb. 11 /PRNewswire-FirstCall/ -- Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY ) announced today that the...
Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
New Data from Landmark
UPLIFT Trial Further Supports Spiriva's Safety
RIDGEFIELD, Conn. and NEW YORK, Sept. 23 /PRNewswire/ -- Boehringer
Ingelheim and Pfizer Inc have released a new analysis of 30 rigorously
controlled clinical trials, including UPLIFT, confirming the long term
TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
PHILADELPHIA, May 12 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK),
in collaboration with the Breast International Group (BIG), a leading
academic breast cancer research network, and one of its member groups, the
Spanish Breast Cancer Cooperative Group (SOLTI), today announced the start
JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
UPPSALA, Sweden and WILMINGTON, Mass., March 7 /PRNewswire/ -- The
Journal of the American College of Cardiology has recognized the five-year
follow-up results of the DEFER (Deferral Versus Performance of PTCA in
Patients Without Documented Ischemia) as one of the studies that had the
Hospital Launches Landmark Emergency Medicine Project
Innovative Concepts for ER One to be Studied for First Time in Patient Setting
WASHINGTON, Jan. 10 /PRNewswire/ -- Washington Hospital Center took a
major step forward today in the federally funded Project ER One initiative
as it unveiled innovative technologies...
Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
LOS ANGELES, Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp.
and the European Organisation for the Research and Treatment of Cancer
(EORTC) announced long-term follow-up results from the landmark
trial conducted by the EORTC and the National Cancer Institute of Canada
Viatronix V3D-Colon Utilized in 'Another' Landmark Study
STONY BROOK, N.Y., Oct. 4 /PRNewswire/ -- Stony Brook based Viatronix
Incorporated (http://www.viatronix.com ), a leading innovator and developer of 3D
imaging software announced today the publication of a new study in the New
England Journal of Medicine, titled "CT Colonography versus Colono...
Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
WAYNE, N.J., Aug. 3 /PRNewswire/ -- Patients treated with Betaseron(R)
(interferon beta-1b) shortly after their first clinical MS event or
"attack" showed a 40 percent lower risk of developing confirmed disability
progression compared to patients in whom treatment was delayed. The
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events
in Landmark Jikei Heart Study
Independent Japanese study demonstrates dramatic
benefits of adding Diovan to conventional therapy
Study halted early due to superior outcomes for
Switzerland, April 27, 2007 - New findings from the independent
Jikei Heart Study, published today in The Lanc...
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events
in Landmark Jikei Heart Study
Independent Japanese study demonstrates ...
Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07
Teleconference to Answer Questions About TA-65, Their Telomerase
Activator With Proven Age Management Benefits NEW YORK, June 15, 2007 /PRNewswire/ -- Telomerase Activation
Sciences, Inc. (T.A. Sciences) recently announced the results of
the Pivotal 2005 Anti-Aging Trial of TA-65, the first human trial
ever to show demonstrated, measurable and positive anti-aging
benefits from a Telomerase Activator. Stati...
MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating
MacroVascular Outcomes Presented at the American Diabetes
Association 67th Scientific Sessions CHICAGO, June 21, 2007 /PRNewswire/ --
What and When
Data from the PROactive and CHICAGO studies of ACTOS(R)
(pioglitazone HCl) will be presented in poster format at the 67th
Scientific Sessions of the American Diabetes Association in
-- Hospitalizations for serious adverse eve...
Neurologix Announces Publication of Landmark Gene Therapy Study
Demonstrating Safety and Statistically Significant Improvement in
Patients With Advanced Parkinson's Disease FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc.
(OTCBB:NRGX) today announced the publication in the June 23 issue
of the journal The Lancet of positive results from the first ever
gene therapy trial for Parkinson's disease and the first report of
direct gene transfer into a patient...
Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results...tional Coalition of state and local organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline on the highly promising results of this landmark clinical trial of Benlysta(TM) (belimumab) for people with systemic lupus.
"We are very hopeful that we now are strongly on our way to the fi...
Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story...ates," says Lisa Newman, M.D., director of the Breast Care Center at the University of Michigan Comprehensive Cancer Center. "However, Dr. Albain's landmark study demonstrates that further investigation of race- or ethnicity-associated differences in primary tumor biology is also important."
Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled... SAN DIEGO, June 30 /PRNewswire/ -- Accumetrics, Inc. announces that it has reached the halfway mark (1,600 patients) in the enrollment of its landmark clinical trial, GRAVITAS ( G auging R esponsiveness with A V erifyNow(R) Assay I mpact on T hrombosis A nd S afety). The trial is specifically ...
New Therapy Found to Prevent Heart Failure... ROCHESTER, N.Y., June 23 /PRNewswire-USNewswire/ -- A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac ...
MADIT-CRT Trial Meets Primary Endpoint... landmark trial shows Boston Scientific CRT-Ds slow the progression of heart failure ...) and the University of Rochester Medical Center today announced that the landmark MADIT-CRT trial has met its primary endpoint. Preliminary results show Bos...
Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons...s to date in patients with high-grade dysplasia and early cancer.
As the DDW meeting commenced, the New England Journal of Medicine published a landmark paper entitled, " Radiofrequency Ablation for Barrett's Esophagus Containing Dysplasia." This is a U.S. randomized sham-controlled trial demonstrati...
Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women...ET).
These presentations are in addition to Genomic Health's previously announced results regarding its Onco type DX colon cancer test, from the landmark QUASAR validation study, demonstrating that the test can independently predict individual recurrence risk in stage II colon cancer patients following ...
SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease...ientific Corporation (NYSE: BSX ) today announced results from an analysis of economic and quality of life outcomes, based on one-year data from its landmark SYNTAX trial. The results found that percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent System...
Juvenile Diabetes Research Foundation to Honor Duane DeSisto of Insulet Corporation and Senator Edward M. Kennedy at 27th Annual Hearts & Heroes Gala...ng through this program has lead to real advances in many areas of type 1 research. Another important piece of legislation is the passing of the 2007 landmark Senate bill that lifted bans on stem cell research in America. Senator Kennedy has been and continues to be a steadfast supporter of stem cell resear...
New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy...ster Medical Center and Principal Investigator of the MADIT, MADIT II and MADIT-CRT trials.
"We are proud to have been the exclusive sponsor of landmark trials like MADIT II," said Fred Colen, President, Boston Scientific Cardiac Rhythm Management. "More than 80 percent of U.S. patients who receive an...
Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine... Data from landmark trial provide important insight for physicians in treating heart attack patients
NATICK, Mass., May 6 /PRNewswire-FirstCall/ -- Boston Scientific...
Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial...ny people have been involved
in the development of Bronchitol and their assistance has been invaluable.
The trial was complex and challenging and this landmark result is a tribute to
Dr Alan Robertson will host a teleconference to discuss the results on
Tuesday 5th May at 8.00am (Sydne...
Optherion Announces Issuance of Canadian Patents Covering Age-Related Macular Degeneration Diagnostics and Treatments...d Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system. Optherion's proprietary technologies are based on landmark scientific discoveries linking certain genes to AMD.
Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet...ngual tablet,
and the basis for further developments in our program" states Albert Saporta,
Chairman and CEO of Stallergenes. "This study is a genuine landmark which
confirms desensitization as a new therapeutic class in the management of
allergic respiratory disorders. Stallergenes has been consolidating its...
Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study...s of active cellular immunotherapies (ACI) specifically designed to engage the patient's own immune system against cancer.
"The results from this landmark study confirm that PROVENGE prolongs survival with a favorable benefit to risk profile," said Paul Schellhammer, MD, professor of urology at Eastern ...
Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap... - designed specifically for low-resource, developing countries
Tiered-pricing initiatives for low-resource countries
"This landmark study further validates the value of QIAGEN's HPV test as the gold standard for cervical cancer screening and demonstrates that the incidence of advan...
SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease...ientific Corporation (NYSE: BSX ) today announced results from an analysis of economic and quality of life outcomes, based on one-year data from its landmark SYNTAX trial. The results found that while the overall cost effectiveness of percutaneous coronary intervention (PCI) versus coronary artery bypass g...
Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study...
Participants Sought For landmark Study To Measure Effects Of Music On Diabetes Outcomes
PAINESVILLE, Ohio, March 11 /PRNewswire/ -- Lake Hospital System today announced that it h...
Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient...rt, thus reducing the risk for perioperative bleeding and stroke associated with having a patient on bypass.
"We are pleased to be a part of this landmark trial evaluating this third-generation mechanical heart pump, one of the first of its kind to enter clinical trials in the U.S.," said Dr. Naka, who s...
Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease... LOS ANGELES, Feb. 16 /PRNewswire/ -- Scientists announced today the
publication of a landmark peer-reviewed paper in the February issue of the
Bentham Open Stem Cell Journal which outlines the long term results of the
world's first clinical tri...
Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer...ce ever identified and a known liver cancer carcinogen, markedly
increases the expression of the targeted microRNA.
"We view this study as a landmark event in the development of microRNA
based cancer therapeutics" said Amir Avniel, President and CEO of Rosetta
Genomics. "While Rosetta's clear focus ...
Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports...ence in these patients from a therapy that was also well-tolerated," said David Epstein, President and CEO of Novartis Oncology. "The findings of this landmark trial substantiate the strong anticancer effect of Zometa beyond the well-established benefit of this treatment in preventing bone complications in ad...
First U.S. Patients Enrolled in the REALISM Continued Access Study...often see patients who may be
candidates for the MitraClip(R) therapy and I am glad they now have an option
to participate in the continuation of this landmark trial and potentially
benefit from this alternative treatment."
The REALISM study is a prospective, multi-center, continued access
registry of ...
AAOMS Updates BRONJ Position Paper... ROSEMONT, Ill., Jan. 22 /PRNewswire-USNewswire/ -- The American Association of Oral and Maxillofacial Surgeons has revised its 2006 landmark position paper on Bisphosphonate-Related Osteonecrosis of the Jaw to reflect the most current research and thought on this condition. BRONJ appears as...
Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer... multi-pronged design
allows us to precisely target distribution of JX-594 for optimal therapeutic
effect. The result is an innovative and potentially landmark combination of a
highly targeted biotherapeutic agent with a sophisticated medical device for
targeted delivery," stated Dr. Kirn.